Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

Legend Biotech (LEGN)

Legend Biotech Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LEGN
DateTimeSourceHeadlineSymbolCompany
03/06/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/06/202421:00Business WireLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
29/05/202413:00Business WireLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
23/05/202422:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/05/202422:00Business WireLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHANASDAQ:LEGNLegend Biotech Corporation
13/05/202412:10IH Market NewsU.S. Futures Climb Amid High Expectations for Inflation Data; Global Markets Show Mixed ReactionsNASDAQ:LEGNLegend Biotech Corporation
13/05/202412:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
13/05/202412:00Business WireLegend Biotech Reports First Quarter 2024 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
22/04/202418:05Business WireCARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/04/202413:00Business WireLegend Biotech to Host Investor Conference Call on First Quarter 2024 ResultsNASDAQ:LEGNLegend Biotech Corporation
06/04/202404:30Business WireLegend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
19/03/202412:30Business WireLegend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) ReportNASDAQ:LEGNLegend Biotech Corporation
15/03/202419:15Business WireCARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:LEGNLegend Biotech Corporation
11/03/202411:52Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
11/03/202411:00Business WireLegend Biotech Reports Fourth Quarter and Full Year 2023 Results and Recent HighlightsNASDAQ:LEGNLegend Biotech Corporation
11/03/202410:39IH Market NewsU.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge HigherNASDAQ:LEGNLegend Biotech Corporation
28/02/202423:46Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LEGNLegend Biotech Corporation
28/02/202400:47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/02/202418:10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
23/02/202412:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/02/202412:15Business WireLegend Biotech Announces Positive CHMP Opinion for CARVYKTI® (ciltacabtagene autoleucel) for the Treatment of Patients with Relapsed and Lenalidomide Refractory Multiple Myeloma in Earlier Lines of TherapyNASDAQ:LEGNLegend Biotech Corporation
15/02/202401:34Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LEGNLegend Biotech Corporation
13/02/202413:00Business WireLegend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2023 ResultsNASDAQ:LEGNLegend Biotech Corporation
23/01/202414:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
23/01/202412:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
09/01/202421:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LEGNLegend Biotech Corporation
03/01/202416:28Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
03/01/202413:30Business WireLegend Biotech Announces Closing of License Transaction for Certain CAR-T Therapies Targeting DLL3NASDAQ:LEGNLegend Biotech Corporation
02/01/202413:30Business WireLegend Biotech to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LEGNLegend Biotech Corporation
27/12/202315:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LEGNLegend Biotech Corporation
 Showing the most relevant articles for your search:NASDAQ:LEGN